XNAS
ACET
Market cap62mUSD
Jul 22, Last price
0.75USD
1D
1.62%
1Q
25.04%
IPO
-95.37%
Name
Adicet Bio Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
42.46%
Rev. gr., 5y
-46.28%
Revenues
0k
Net income
-117m
L-17.90%
CFO
-92m
L-1.43%
Dividend
Sep 21, 20180.0014 USD/sh
Earnings
Aug 11, 2025
Profile
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 24,990 156.83% | ||||||||
Cost of revenue | 127,615 | 138,674 | 102,550 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (127,615) | (138,674) | (77,560) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (2,761) | ||||||||
Tax Rate | |||||||||
NOPAT | (127,615) | (138,674) | (74,799) | ||||||
Net income | (117,122) -17.90% | (142,658) 112.83% | (67,029) 8.11% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 110,918 | 236 | 40,126 | ||||||
BB yield | -131.22% | -0.29% | -10.93% | ||||||
| Debt | |||||||||
Debt current | 3,132 | 6,442 | 2,492 | ||||||
Long-term debt | 31,336 | 38,627 | 39,554 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 116 | 130 | 114 | ||||||
Net debt | (141,835) | (114,642) | (215,610) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (92,378) | (93,717) | (44,765) | ||||||
CAPEX | (1,118) | (4,464) | (16,782) | ||||||
Cash from investing activities | (119,242) | (4,464) | (16,782) | ||||||
Cash from financing activities | 111,307 | 236 | 41,509 | ||||||
FCF | (120,166) | (133,896) | (88,777) | ||||||
| Balance | |||||||||
Cash | 176,303 | 159,711 | 257,656 | ||||||
Long term investments | |||||||||
Excess cash | 176,303 | 159,711 | 256,406 | ||||||
Stockholders' equity | (497,870) | (380,768) | (238,110) | ||||||
Invested Capital | 701,829 | 575,218 | 21,133 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 87,866 | 43,042 | 41,080 | ||||||
Price | 0.96 -49.10% | 1.89 -78.86% | 8.94 -48.89% | ||||||
Market cap | 84,528 3.91% | 81,350 -77.85% | 367,258 -32.16% | ||||||
EV | (57,307) | (33,292) | 151,648 | ||||||
EBITDA | (122,815) | (132,576) | (74,985) | ||||||
EV/EBITDA | 0.47 | 0.25 | |||||||
Interest | 4 | 80 | |||||||
Interest/NOPBT | |||||||||